%PDF-1.4
%
29 0 obj
<>
endobj
26 0 obj
<>
endobj
80 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-01-05T12:03:45Z
2024-03-29T00:29:22-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T00:29:22-07:00
application/pdf
Heather
2003-768.feb
uuid:a2d4961a-1dd1-11b2-0a00-8709278d5b00
uuid:a2d4961c-1dd1-11b2-0a00-1e0000000000
endstream
endobj
15 0 obj
<>
endobj
16 0 obj
<>
endobj
30 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 7 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 9 0 R/Type/Page>>
endobj
86 0 obj
[90 0 R]
endobj
87 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.005 Tc 0.1729 Tw 10 0 0 10 54 713.1616 Tm
(for most of these potential confounders. One of the more)Tj
-0.0051 Tc 0.0246 Tw 0 -1.21 TD
(important factors influencing drug utilization may be cost to)Tj
0.0658 Tw T*
[(the patient. )17.6 (There is a considerable dif)17.6 (ference in cost of the)]TJ
0.10789 Tw T*
(nonselective NSAID \(NSNSAID\) versus cyclooxygenase-2)Tj
0.01489 Tc 0.442 Tw T*
(selective NSAID \(CSNSAID\). In 2001, the average)Tj
-0.0051 Tc 0.2095 Tw T*
[(cost/prescription for Celebrex and )17.6 (V)59.8 (ioxx was $97.32 and)]TJ
T*
[($85.44, respectively)64.8 (, while the average cost for naproxen)]TJ
0.0052 Tw T*
(was $24.90 and that for ibuprofen was even less)Tj
0 Tc 0 Tw 6.5 0 0 6.5 244.4888 631.7617 Tm
(9)Tj
-0.0051 Tc -0.0126 Tw 10 0 0 10 247.7063 628.4617 Tm
[(. The )-17.7 (prices)]TJ
0.19949 Tw -19.3706 -1.21 Td
[(for the CSNSAID have continued to increase. )17.5 (While this)]TJ
0.0387 Tw T*
(might not be an important consideration for some, for many)Tj
0.08929 Tw T*
[(it is the deciding factor)39.6 (, especially for older patients taking)]TJ
0.37041 Tw T*
(multiple brand-name medications. In their analysis, the)Tj
0.1539 Tw T*
(authors have controlled for age, income, functional status,)Tj
0.22881 Tw T*
[(education, race, and sex. )17.7 (While they have not controlled)]TJ
0.1772 Tw T*
(directly for insurance status and medication coverage, the)Tj
0.039 Tw T*
(variables employed are likely correlated and should account)Tj
0.2009 Tw T*
[(for this influence. )54.7 (And, in response to a question from a)]TJ
0.20441 Tw T*
[(reviewer)39.7 (, the authors confirm that insurance type did not)]TJ
-0.0312 Tw T*
(influence the results, but point out that not all insurance plans)Tj
0.271 Tw T*
(have the same medication coverage. In addition, not all)Tj
0.3362 Tw T*
(insurance plans have the same co-payments for similar)Tj
0.07359 Tw T*
[(CSNSAID. )17.7 (There are preferred and nonpreferred formulary)]TJ
0.28419 Tw T*
(CSNSAID, and financial disincentives have been put in)Tj
0.18021 Tw T*
(place by some plans to influence medication choice. It is)Tj
0.04559 Tw T*
[(dif)17.7 (ficult, at best, to control for these influences. However)39.6 (, it)]TJ
-0.0211 Tw T*
[(could also be ar)17.7 (gued that financial disincentives would likely)]TJ
0.2368 Tw T*
(decrease the time on drug for CSNSAID \(in general\) in)Tj
0.0994 Tw T*
(comparison to NSNSAID if out-of-pocket expenses for the)Tj
0.1851 Tw T*
[(former were significantly greater)54.7 (. But cost pressure could)]TJ
0.0591 Tw T*
(influence the decision as to which CSNSAID is chosen and)Tj
0.02499 Tw T*
(how long that particular CSNSAID is taken.)Tj
-0.00011 Tc -0.02229 Tw 1.2 -1.2 Td
[(It seems likely)64.8 (, although unproven, that advertising could)]TJ
0.06 Tw -1.2 -1.2 Td
(influence duration of use. It appears to increase drug sales.)Tj
0.0363 Tw 0 -1.2 TD
(There was a 24.6% increase in sales of the 50 most heavily)Tj
0.11591 Tw T*
(advertised drugs versus 4.3% increase for all others drugs)Tj
0.2467 Tw T*
[(from 1999 to 2000. For )17.7 (V)59.8 (ioxx, the single most heavily)]TJ
0.0071 Tw T*
(advertised drug to consumers in the year 2000, with promo-)Tj
-0.0302 Tw T*
(tional expenditures of over $160 million, retail sales quadru-)Tj
0.02499 Tw T*
(pled from $329.5 million in 1999 to $1.5 billion in 2000)Tj
0 Tc 0 Tw 6.5 0 0 6.5 281.4904 257.4619 Tm
(10)Tj
10 0 0 10 287.9903 254.1619 Tm
(.)Tj
-0.0051 Tc 0.01089 Tw -22.199 -1.2 Td
(I would agree with the authors that it may not be possible)Tj
-0.03 Tw -1.2 -1.2 Td
[(to precisely determine the magnitude of the ef)17.6 (fect, but the net)]TJ
0.0096 Tc 0.36031 Tw T*
(result is undoubtedly an increase in prescriptions for)Tj
-0.0051 Tc -0.0005 Tw T*
(CSNSAID. In many cases, a new prescription for CSNSAID)Tj
0.13589 Tw T*
(results in the termination of an existing NSNSAID, which)Tj
-0.0047 Tw T*
(otherwise might not have been terminated, at least not at that)Tj
0.1978 Tw T*
[(time. )17.7 (The ef)17.7 (fect of advertising is to raise expectations of)]TJ
0.2002 Tw T*
[(benefit. Most patients who came into my of)17.6 (fice after the)]TJ
0.2393 Tw T*
[(approval of celecoxib and rofecoxib didn\325)17.6 (t ask for these)]TJ
0.0025 Tc 0.3674 Tw T*
(medications because they heard they were safer; they)Tj
-0.0051 Tc -0.0045 Tw T*
(requested them because they had been encouraged to believe)Tj
0.2834 Tw T*
[(that they were more ef)17.6 (fective. )17.7 (These expectations could)]TJ
0.02499 Tw T*
(influence duration of use.)Tj
0.1046 Tw 1.2 -1.2 Td
[(Finally)64.8 (, the measurement of drug survival does not take)]TJ
-0.02589 Tw -1.2 -1.2 Td
[(into account or weigh the reasons for termination. )17.5 (These may)]TJ
0.0619 Tw 26.4 63.9 Td
(be important and could change the fundamental risk/benefit)Tj
0.25369 Tw T*
[(equation. For example, not all side ef)17.6 (fects that result in)]TJ
-0.0024 Tc 0.3723 Tw T*
[(discontinuation are equally significant. )17.8 (This method of)]TJ
-0.0051 Tc 0.1358 Tw T*
(analysis treats terminations for fatal gastrointestinal bleeds)Tj
0.0069 Tw T*
(the same as those for a rash. If 2 drugs had the same average)Tj
0.14011 Tw T*
(survival time, but one caused twice the number of deaths,)Tj
0.1288 Tw T*
[(one wouldn\325)17.7 (t necessarily conclude that the 2 were equiva-)]TJ
0.10471 Tw T*
(lent. Some measure of severity of toxicity is also required,)Tj
-0.0338 Tw T*
(such as the toxicity index proposed by Fries and colleagues)Tj
-0.06171 Tc 0 Tw 6.5 0 0 6.5 549.4338 620.4615 Tm
(11)Tj
0 Tc 10 0 0 10 555.5001 617.1616 Tm
(.)Tj
-0.00011 Tc 0.0321 Tw -22.55 -1.2 Td
(The conclusions of the analysis reported here are clearly)Tj
-0.01849 Tw -1.2 -1.2 Td
[(strengthened by the lar)17.7 (ge number of subjects who have been)]TJ
0.1543 Tw T*
(recruited from a multitude of practices located across the)Tj
0.17979 Tw T*
[(country)64.8 (. )17.7 (The numbers of subjects and their heterogeneity)]TJ
0.1554 Tw T*
(may overcome some of the concerns listed above. If that)Tj
0.12579 Tw T*
(were the case, then the questions that must now be asked)Tj
0.004 Tw T*
[(are: do the dif)17.7 (ferences detected represent a meaningful clin-)]TJ
0.0249 Tw T*
[(ical dif)17.7 (ference; and, are those dif)17.7 (ferences worth the cost?)]TJ
/T1_2 1 Tf
7.7 -2.4 Td
[(MICHAEL)-220.2 (E. LUGGEN,)]TJ
/T1_1 1 Tf
6 0 0 6 506.5899 497.1616 Tm
[(MD, F)73.8 (ACP)110.7 (,)]TJ
8 0 0 8 395 487.1616 Tm
(Associate Professor of Clinical Medicine,)Tj
0 -1.25 TD
[(Division of Immunology)64.8 (,)]TJ
T*
[(University of Cincinnati Medical Sciences Center)39.7 (,)]TJ
0 Tc T*
[(231 Bethesda )54.8 (A)74 (venue, Room 7464, )]TJ
-0.00011 Tc T*
(Cincinnati, Ohio 45267-0563 USA)Tj
/T1_3 1 Tf
-9.625 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. Luggen. E-mail: luggenme@ucmail.uc.edu)]TJ
/T1_2 1 Tf
0 Tw 10 0 0 10 318 403.1616 Tm
(REFERENCES)Tj
/T1_1 1 Tf
-0.0201 Tc 0.02499 Tw 8 0 0 8 325.16 393.3616 Tm
[(1.)-895.1 (Hippocrates. )17.7 (The aphorisms of Hippocrates. )17.6 (T)35 (ranslated by )17.7 (Thomas)]TJ
1.655 -1.225 Td
[(Coar)54.8 (. Birmingham, )54.8 (Alabama: Classics of Medicine Library; 1982.)]TJ
-1.655 -1.2 Td
[(2.)-895.1 (Sokka )17.7 (T)74 (, Pincus )17.7 (T)74 (. Eligibility of patients in routine care for major clin-)]TJ
1.655 -1.2 Td
(ical trials of anti-tumor necrosis factor alpha agents in rheumatoid)Tj
0 -1.2 TD
[(arthritis. )54.8 (Arthritis Rheum 2003;48:313-8.)]TJ
-1.655 -1.2 Td
[(3.)-895.1 (W)79.9 (olfe F)79.7 (, Michaud K, Burke )17.7 (T)79.9 (A, Zhao SZ. Longer use of COX-2)]TJ
1.655 -1.2 Td
(specific inhibitors compared to nonspecific NSAID: a longitudinal)Tj
T*
(study of 3639 patients in community practice. J Rheumatol)Tj
0 Tw T*
(2004;31:355-8. )Tj
0.02499 Tw -1.655 -1.2 Td
[(4.)-895.1 (Rooney PJ, Capell HA, Paterson S, Buchanan )17.6 (WW)91.7 (, Dick )17.7 (WC.)]TJ
1.655 -1.2 Td
[(Continued use of non-steroidal anti-inflammatory drugs: )54.6 (An index of)]TJ
T*
[(clinical ef)17.7 (ficacy)64.8 (. Br J Clin Pharmacol 1978;5:453-5. )]TJ
-1.655 -1.2 Td
[(5.)-895.1 (Luggen ME, Gartside PS, Hess EV)128.7 (. Nonsteroidal anti-inflammatory)]TJ
1.655 -1.2 Td
(drugs in rheumatoid arthritis: duration of use as a measure of relative)Tj
T*
(value. J Rheumatol 1989;16:1565-9.)Tj
-1.655 -1.2 Td
[(6.)-895.1 (W)39.9 (ijnands M, van Riel P)110.7 (, van\325)17.7 (t Hof M, Gribnau F)79.7 (, van de Putte LBA.)]TJ
1.655 -1.2 Td
(Longterm treatment with nonsteroidal anti-inflammatory drugs in)Tj
T*
[(rheumatoid arthritis: a prospective drug survival study)64.7 (. )]TJ
T*
(J Rheumatol 1991;18:184-7.)Tj
-1.655 -1.225 Td
[(7.)-895.1 (Pincus )17.7 (T)74 (, Marcum SB, Callahan LF)79.6 (, et al. Longterm drug therapy for)]TJ
1.655 -1.225 Td
(rheumatoid arthritis in seven rheumatology private practices: I.)Tj
0 -1.225 TD
(Nonsteroidal anti-inflammatory drugs. J Rheumatol 1992;19:1874-84.)Tj
-1.655 -1.225 Td
[(8.)-895.1 (Scholes D, Ster)17.7 (gachis )54.8 (A, Penna PM, Normand EH, Hansten PD.)]TJ
1.655 -1.225 Td
(Nonsteroidal anti-inflammatory drug discontinuation in patients with)Tj
T*
(osteoarthritis. J Rheumatol 1995;22:708-12.)Tj
-1.655 -1.225 Td
[(9.)-895.1 (National Institute of Health Care Management Research and Education)]TJ
1.655 -1.225 Td
[(Foundation. Prescription drug expenditures in 2001: )54.7 (Another year of)]TJ
T*
[(escalating costs. )17.7 (W)80 (ashington, DC; May 6, 2002:15.)]TJ
-2.135 -1.225 Td
[(10.)-895.1 (The National Institute of Health Care Management Research and)]TJ
2.135 -1.225 Td
(Education Foundation. Prescription drugs and mass media )Tj
-0.00011 Tc 0 Tw 22.6048 0 Td
(advertising,)Tj
0 Tc 0.02499 Tw -22.6048 -1.225 Td
[(2000. )17.8 (W)80 (ashington, DC; Nov 2001:2. )]TJ
-0.00011 Tc -2.1381 -1.225 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Fries JF)79.7 (, )17.7 (W)39.9 (illiams CA, Bloch DA. )17.7 (The relative toxicity of)]TJ
2.1381 -1.225 Td
[(nonsteroidal anti-inflammatory drugs. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1991;34:1353-60.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:2)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(206)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
9 0 obj
<>stream
8;Z\7>B0ii#itt$j>s9_#_ITdC\"Fc,FR7sg?oa'7Jt(Or_u-A1's.HERsU.Llk0q
XZ=/!BLMY]i(n&XA)\Y05QSCm:53YPl$cd8R>od$EH6d
kfJ5FY"&B+SAsg4oWk5k;/)qoeJa(Y_i$+C*n,@CXUST[7^$BWG]8KeTm:!DO!S)cUX*i8C
O6meTR`('o2R1mXjpr[1%oi-OYCT0KRJU/M:L__8-kp:'U9Z\nUQp,MC7JG5H/2rN
B%Yj8Xr5VmkjN%O@g-6S5kB%Fjd59)YTf5SP:gRq&+?:0.P4#Q"^:J-I(rBFeOO_o
V^^RGPlsS3j:RR*-k*9t6"sS>8$"Kb.YNrZmTg-!L%R&T%0kX*\L=!V9h;_q'`GqSfq#e6(8=fJI_ahfp4NYdd*-b_sk'
517M@ei>f3:a@aFOupn,!Qi(n#%q,XMatIn0mRsV"&g5ArEJ0Wj*P'D11GZCq=]1"
R#_uL7LDG,
Sl.M6/W9"Op>[75f)WH_aG9~>
endstream
endobj
13 0 obj
[/Indexed/DeviceRGB 255 12 0 R]
endobj
12 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
75 0 obj
<>
endobj
32 0 obj
<>
endobj
4 0 obj
<>
endobj
35 0 obj
<>
endobj
70 0 obj
<>
endobj
85 0 obj
<>
endobj
34 0 obj
<>
endobj
58 0 obj
<>stream
HlT{PSgpo.6F^""UtW+-"
`yDIx$!ޏ@%PT@k+>Xl+
:eڞݨ͜;;3\ޞ+|vEx8#V8þkQHb3̳dyh}%4*,|cy\6
vkm1ǩʦ>g5Nή[ J8:F,f+_=J!brH"gGJe RYB0qqk"Y1#3B%b!G/U(DZ*cf<)B."o}10>ِ pl!-
Z`aB0La+Jba.X߄_(8V0,%ppVRV6kTtޥ٪3|wȜskK%`QNH$L~os6'77'5KII-8ƁCӎtp\\h^"Z\ʳ+=yP|Jg48MB՝B߸ŁJ%hT$%uIa]e¥ l=[7tSo)o0Ʃ˔izɸ^l Y1Jq3a"G*=\J4}8$h?_
xřN}rPJphuDg*eH:O6,l#7'(և@3>4J"a|{u6bډF(V:hzmU'ɛbV͉HH;ʅ5rF+6RH~vx
x]h~iJZtCW_/OLӁtrRd]RY](9⭠ܷ +%zQ@47D^,=[Җݝ!vYq&78d[}khF5^t$)'-Tۛ] jn܇o]}}Cy<\t/eU3XwԕqEG]@hyϛ;F{n
ݟRvȟ6ڽ{3GX۩[]χ7)0LᏦ8iKÞo垰
sI}eW[5I1Eie6YթHi\*']6
xXo-^C{u;au7{pg6&6VV Iԩ\R⇠YK{\d䞯;V{h])T5cE`]ְ(V`9+0_* 5> 8.쌻նڻmZ_%`
ԀR`sGNzBynh=+HvW HF=VwGmsIG64!
.6/5?<&"d(y}bNFiᰶӮ!WKcKF@iBK@$#4r o>
",^xg崒1QpV&HxaUrϨ?bW}
O4ګah]ɺ+rGUзk:1#!ƕ-&"P||{qAjU8u|26+ާl"U`D&%tW%DKft8!ZQT_l#;27`kuSѳ;Ư=/g5WboUŽ ~ieڃwh~'T2삆n